• 15-PGDH Inhibition and Muscle Repair During Weight Loss

  2026-10-07

  A 2026 PNAS study reports that 15-PGDH inhibition improved muscle stem cell activity, regenerated myofiber growth, and strength recovery in obese mice receiving semaglutide after muscle injury. The findings identify a potential complementary research strategy for preserving muscle quality during pharmacological weight loss, while remaining preclinical and dependent on a specific injury and obesity model.

• Acridine Orange Hydrochloride: Product Overview

  2026-10-06

  Acridine Orange hydrochloride is a supplier-described fluorescent nucleic acid dye. The available information documents its identity, formula, molecular weight, and intended conceptual scope, but no matched paper evidence was provided to establish performance or application-specific validity.

• Natural Vitamins for SARS-CoV-2 Target Discovery

  2026-10-06

  Eskandari et al. used molecular docking and molecular dynamics to examine natural vitamins as potential ligands for the SARS-CoV-2 main protease and spike receptor-binding domain. The findings generate hypotheses for antiviral therapeutics research, but they remain computational and require biochemical, cellular, pharmacological, and clinical validation.

• qRT-PCR Context for NSCLC Metastasis Research

  2026-10-05

  A source-grounded overview of how reverse-transcription qPCR can support gene expression analysis in NSCLC metastasis research, using the 2026 iScience study of the SPI1/miR-616-5p axis as context. It distinguishes reported findings from supplier claims about HyperScript™ RT SuperMix for qPCR and explains evidence strength, assay boundaries, translational limitations, and why expression data alone cannot establish therapeutic efficacy or mechanism.

• Palonosetron and Chemotherapy-Induced Nausea and Vomiting

  2026-10-05

  Ruhlmann and Herrstedt’s review examines why palonosetron may differ from earlier 5-HT3 receptor antagonists, emphasizing its long half-life, high receptor affinity, allosteric binding, and positive cooperativity. The paper also places these pharmacologic features in clinical context, showing that potential advantages must be judged by efficacy, tolerability, treatment phase, and combination therapy rather than mechanism alone.

• RSL3, PARP1, and Ferroptosis–Apoptosis Crosstalk

  2026-10-04

  The 2025 study by Chen and colleagues identifies PARP1 as a mechanistic bridge between RSL3-induced ferroptosis and apoptosis, describing both caspase-dependent PARP1 cleavage and reduced full-length PARP1 production. Its findings extend the interpretation of RSL3 beyond GPX4 inhibition and suggest relevance to PARP inhibitor-resistant tumor models, while remaining dependent on the study’s cancer-cell and xenograft systems.

• Sodium Pyruvate in Animal Pharming Research

  2026-10-03

  Sodium pyruvate is more than a routine cell-culture supplement: its metabolic effects can shape how recombinant-protein studies are interpreted. This article examines its biochemical context alongside the targeted rabbit pharming strategy reported by Song et al., separating demonstrated findings from plausible but untested connections.

• Sodium Pyruvate and the Next Pharming Platform

  2026-10-02

  A targeted rabbit pharming study shows how promoter choice, precise genome editing, and inherited alleles can move recombinant protein production beyond the variability of conventional transgenesis. This article translates those findings into a strategic framework for researchers evaluating metabolic controls, assay design, and the translational role of Sodium pyruvate.

• SW033291: A 15-PGDH Assay-to-Repair Framework

  2026-10-01

  SW033291 is a potent 15-PGDH inhibitor for connecting prostaglandin E2 elevation with tissue repair biology. This article develops an assay-to-phenotype framework for interpreting muscle regeneration, hematopoiesis, and target-engagement data without confusing compound-specific evidence with broader 15-PGDH biology.

• Spatial PD-L1–IL-6 Crosstalk in PSC

  2026-10-01

  Orlandi and colleagues use spatial proteomics and cell-cell cross-talk analysis to examine how PD-L1 and IL-6 are organized at the epithelial–immune interface in human primary sclerosing cholangitis. The study’s main contribution is a spatial framework for interpreting coupled immune-checkpoint and inflammatory signals, while its findings also define important limits for causal and therapeutic extrapolation.

• gamma-Glu-Cys: Practical Assay and Workflow Guide

  2026-09-30

  gamma-Glu-Cys provides a defined, soluble intermediate for glutathione synthetase assays, glutathione metabolism research, and carefully controlled γ-glutamyl peptide experiments. This guide translates recent Bacillus fermentation findings into practical substrate controls, workflow choices, and troubleshooting steps while keeping product specifications separate from experimental recommendations.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-09-30

  The reference study combines genetic ablation, inducible mouse modeling, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia. Its findings position FGFR3 inhibition, including treatment with NVP-BGJ398, as a mechanistically supported strategy for improving chondrocyte differentiation and skeletal architecture, while leaving important translational questions unresolved.

• DAPI Solution (1 mg/mL): Nuclear Assay Guide

  2026-09-29

  DAPI, or 4',6-Diamidino-2-Phenylindole, is a DNA-binding fluorescent stain for nuclear visualization, fixed-cell imaging, and selected flow cytometry workflows. The K2401 DMSO stock supports reproducible assay setup, but DAPI signal alone cannot establish apoptosis, viability, or exosome mechanism.

• Bay 11-7085: Mapping NF-κB–Apoptosis Coupling

  2026-09-29

  Bay 11-7085 is an NF-κB activation inhibitor that can connect inflammatory signaling with cell-cycle control and apoptosis. This guide develops a pathway-mapping strategy informed by endoplasmic-reticulum-stress research, while clarifying what the probe can—and cannot—prove in cellular and animal models.

• PBA-Targeted PAD4 Inhibitors and Tumor NETs

  2026-09-28

  This study develops phenylboronic acid (PBA)-modified PAD4 inhibitors designed to concentrate activity in tumors while suppressing the PAD4–H3cit–NETs pathway in neutrophils. The lead compound 5i inhibited tumor growth and lung metastasis in mouse models, providing a targeting strategy that links tumor-cell recognition with modulation of the tumor immune microenvironment.

8680 records 5/579 page Previous Next 12345 下5页 Last page